Issue 2 2021

CEO MONTHLY / ISSUE 2 2021 5 , Currently, Mr. Guthrie is the Chief Information Officer at ShareCare and founder of Guthrie Technology Services. “I am super excited to have David Guthrie as our newest board member,” said David Wise, CEO and Founder of AVOXI. “He joins our organisation at an exciting time, as we’ve just expanded our voice coverage presence by 40% and witnessed incredible adoption growth of our agile contact centre platform, which was a major focus of ours this past year. Appointing David will be an invaluable addition to our company, and I look forward to his contributions as we continue to execute strategy, drive profitable growth, and strengthen the organisational value for our shareholders.” Mr. Guthrie has over 30 years of experience in leadership roles, including Chief Technology Officer, Chief Strategy Officer, and Chief Product Officer, for private and public technology companies. Mr. Guthrie was a co-founder of Medcast, a healthcare news and information system company, which later sold to WebMD in a four-way merger. During his tenure at PGi as Chief Technology Officer, Mr. Guthrie led the development of its hybrid global VoIP collaboration network that sold for $1.1 billion in 2015 to Siris Capital. He is a recipient of the Georgia Chief Information Officer Lifetime Achievement Award and is the proud owner of 20+ patents. Mr. Guthrie is an alumnus of The University of Tennessee- Knoxville with a Bachelor of Science degree in Management and Information Systems. With a strategic combination of business acumen, strategic planning, and creative problem solving, David Guthrie has a fantastic skillset to lend to AVOXI. Going forward, Mr. Guthrie will be working closely with the AVOXI leadership team to further refine product strategy and innovation across the AVOXI global communications platform. “I am excited to work with AVOXI and have really enjoyed my initial time with the team. It is a great group of people who are focused on solving customers’ problems with technology solutions,” noted Guthrie. “Additionally, I am looking forward to helping them shape the product roadmap and software feature set over the coming months.” Mr. Guthrie completes the AVOXI board of directors, which also includes serial software veteran, Wain Kellum, CEO of SpaceIQ and technology investor, Paul Johan, Partner at Ballast Point Ventures. Looking ahead, AVOXI’s newly expanded leadership and advisory team is poised to set up the company for continued growth in 2021 and beyond. Raymond De Vré will join PolyPeptide Group as CEO elect on 1 April 2021 and will work alongside Jane Salik during a transition period prior to taking up his role as CEO over the course of the summer. Jane Salik will remain a member of the Executive Committee until the summer of 2021, after which she will continue to focus on her role on the Board of Directors. Raymond De Vré joins from Dr. Reddy’s Laborato- ries, a leading multinational pharma¬ceutical com- pany based in India, where he is a member of the Management Council and Global Head of Biologics. Over the past eight years, he has helped to grow the biologics business by expanding it international- ly, increasing the manufacturing capacity multi-fold and building a robust product pipeline in oncology and immunology. Prior to this, Raymond De Vré spent 15 years with McKinsey & Company, where he was a Partner advising pharma¬ceutical, biotech and special- ty chemical companies in Europe, the US and India on M&A, growth strategies and operational improvements. He is a Belgian national and holds a master’s degree in engineering from Université Li- bre de Bruxelles (ULB) as well as a PhD in applied physics from Stanford University. Jane Salik has been with PolyPeptide Group since its incorporation as an independent company in 1996 and has more than quadrupled peptide sales and profits since 2006, when she became CEO. She has been responsible for PolyPeptide Group’s expansion into new geographies across facilities, and has established a culture of innovation and execution of best practice. Commenting on the changes, PolyPeptide Group Chairman, Jeffrey Hobbs, stated: “The Board is delighted to have appointed Dr. Raymond De Vré to the PolyPeptide Group as our next CEO. With more than two decades of relevant experience in the industry, Dr. Raymond De Vré is a respected leader in the life sciences community, bringing skills and expertise which will make signifi- cant contributions to our continued long-term growth. “On behalf of the entire PolyPeptide Group, I would like to thank Jane for her role in PolyPeptide Group’s growth during her outstanding tenure with the company. Her insights and leadership have guided us through a period of significant growth and I’m pleased that we will continue to benefit from her expertise as a member of the Board of Directors.” Adding onto this, was incoming Chief Executive Officer, who said: “I am proud to join a company and management team with such exceptional industry knowledge, strong customer focus, unique culture, and track record of success. I am looking forward to building on these many successes to keep growing the PolyPeptide Group business in the years to come, capturing opportunities driven by innovation in the pharmaceutical and biotech industry.” Invaluable Addition AVOXI, a global Communications Platform as a Service (CPaaS) company, is pleased to announce the appointment of technology- veteran David Guthrie to the company’s board of directors.